Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Offer a Superior Survival Advantage in Malignant Glioma ( Journal of immunology. 2015 Jul 1;195(1):367-76.)

報告日期: 2015/11/27
報告時間: 3:10/4:00
報告學生: 袁俊文
講評老師: 曾淑芬
附件下載: 下載[1530-1443056110-1.pdf] 

Dendritic cell–based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma

Mahua Dey, Alan L. Chang, Jason Miska, Derek A. Wainwright, Atique U. Ahmed, Irina V. Balyasnikova, Peter Pytel, Yu Han, Alex Tobias, Lingjiao Zhang, Jian Qiao, Maciej S. Lesniak

J Immunol. 2015 Jul 1;195(1):367-76. doi: 10.4049/jimmunol.1401607.

Speaker:  Chun-Man Yuen (袁俊文)                             Time: 15:10~16:00, 11/27 Commentator: Prof. Tzeng Shun-Fen (曾淑芬老師)       Place: Room 602

Abstract:

Malignant glioma is a kind of ill-defined infiltrating brain tumor with poor prognosis and composed of about 51% of all gliomas.1 Even aggressive treatment strategy including resection, chemotherapy and radiotherapy, the median survival rate is about 12~21 months.1,3 Investigation on further means of effective treatment are urgently needed. It is known that tumorgenesis may relate to tumor cell escaped from host immune system and develop into cell cluster that cannot be recognized and defended by host scavenger cell.2 Current research made effect to re-educate the host immune system to recognize the tumor cell as foreign part.4 The critical issue in this immunotherapy is to arouse the host immune cell from immune-suppressive status to immune-active form. This article investigate the behavior of two distinct subsets of dendritic cells (plasmacytoid cells and myeloid cells), the distribution of their abundance, the immune reaction to tumor progression, and the potential as vaccines candidate.

 References:

  1. Bovenberg MS, Degeling MH, Tannous BA: Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther 21:1297-1305, 2013
  2. Bruttel VS, Wischhusen J: Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol 5:360, 2014
  3. Seymour T, Nowak A, Kakulas F: Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front Oncol 5:159, 2015
  4. Yang L, Guo G, Niu XY, Liu J: Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int 2015:717530, 2015